AstraZeneca PLC Stock Forecast for 2022 - 2025 - 2030

Updated on 09/27/2022

Stock Rating
18
Price Target
£142.37
Consensus
Outperform
Upside
43.33%
Analysts
13
Stock Rating
18
Upside
43.33%
Analysts
13
Price Target
£142.37

AstraZeneca PLC Stock Forecast and Price Target

AstraZeneca PLC has an average price target of £142.37 recently offered by thridteen notable experts for 2022, which would represent a potential upside of approximately 43.33% from the last closing price in September, 2022 if reached. This potential increase is based on a high estimate of £201.79 and a low estimate of £83.61. If you're looking to buy AstraZeneca PLC stock, you may also want to check out its rivals.

£142.37

43.33% Upside

Outperform
Outperform

AstraZeneca PLC Fair Value Forecast for 2022 - 2025 - 2030

AstraZeneca PLC's Price has grown in the last three years, jumping from £59.51 to £90.99 – an increase of 52.89%. In the next year, analysts predict that Fair Value will reach £102.54 – an increase of 12.70%. For the next nine years, the forecast is for Fair Value to grow by 198.83%.

2022 Fair Value Forecast
£102.54
2023 Fair Value Forecast
£119.02
2024 Fair Value Forecast
£138.51
2025 Fair Value Forecast
£156.61
2026 Fair Value Forecast
£177.21
2027 Fair Value Forecast
£199.22
2028 Fair Value Forecast
£221.95
2029 Fair Value Forecast
£246.30
2030 Fair Value Forecast
£271.90
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
JNJ Stock Forecast Johnson & Johnson Outperform 12
$165.70 Buy/Sell $185.07 9.84%
LLY Stock Forecast Eli Lilly and Outperform 16
$307.50 Buy/Sell $333.19 13.82%
ABBV Stock Forecast AbbVie Outperform 9
$141.21 Buy/Sell $164.23 10.47%
PFE Stock Forecast Pfizer Outperform 3
$43.83 Buy/Sell $56.27 20.92%
MRK Stock Forecast Merck Outperform 6
$86.18 Buy/Sell $99.57 16.04%

AstraZeneca PLC Revenue Forecast for 2022 - 2025 - 2030

AstraZeneca PLC's Revenue has grown in the last three years, jumping from £22.09B to £37.42B – an increase of 69.38%. In the next year, analysts predict that Revenue will reach £43.24B – an increase of 15.55%. For the next nine years, the forecast is for Revenue to grow by 235.44%.

2022 Rev Forecast
£43.24B
2023 Rev Forecast
£50.55B
2024 Rev Forecast
£60.11B
2025 Rev Forecast
£68.89B
2026 Rev Forecast
£78.80B
2027 Rev Forecast
£89.63B
2028 Rev Forecast
£100.80B
2029 Rev Forecast
£112.80B
2030 Rev Forecast
£125.51B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
NOVO B Stock Forecast Novo Nordisk A/S Outperform 18
kr741.60 Buy/Sell kr678.96 20.69%
ABT Stock Forecast Abbott Laboratories Outperform 14
$99.84 Buy/Sell $128.88 26.20%
NOVN Stock Forecast Novartis Hold 18
CHF73.98 Buy/Sell CHF103.75 20.40%

AstraZeneca PLC Dividend per Share Forecast for 2022 - 2025 - 2030

In the last three years, AstraZeneca PLC's Dividend per Share has increased by 2.50%, going from £2.80 to £2.87. In the next year, analysts are expecting an increase in Dividend per Share, predicting it will reach £2.89 – an increase of 0.81%. The AstraZeneca PLC forecast is for Dividend per Share to reach £3.18 or grow by 10.88%.

2022 DPS Forecast
£2.89
2023 DPS Forecast
£2.92
2024 DPS Forecast
£2.97
2025 DPS Forecast
£3.00
2026 DPS Forecast
£3.04
2027 DPS Forecast
£3.07
2028 DPS Forecast
£3.11
2029 DPS Forecast
£3.15
2030 DPS Forecast
£3.18
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BMY Stock Forecast Bristol-Myers Squibb Outperform 2
$70.15 Buy/Sell $79.05 18.32%
AMGN Stock Forecast Amgen Hold 9
$226.87 Buy/Sell $246.51 12.40%
MDT Stock Forecast Medtronic Outperform 18
$81.33 Buy/Sell $106.84 30.33%

AstraZeneca PLC Free Cash Flow Forecast for 2022 - 2025 - 2030

AstraZeneca PLC's Free Cash Flow has increased by 209.33% In the last three years, going from £1.58B to £4.87B. In the next year, analysts expect Free Cash Flow to reach £6.34B – an increase of 30.07%. For the next nine years, the forecast is for Free Cash Flow to grow by 449.31%.

2022 FCF Forecast
£6.34B
2023 FCF Forecast
£8.29B
2024 FCF Forecast
£10.17B
2025 FCF Forecast
£12.38B
2026 FCF Forecast
£14.84B
2027 FCF Forecast
£17.46B
2028 FCF Forecast
£20.34B
2029 FCF Forecast
£23.45B
2030 FCF Forecast
£26.76B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
CSL Stock Forecast CSL Outperform 16
$284.81 Buy/Sell $228.01 -22.67%
GILD Stock Forecast Gilead Sciences Outperform 11
$62.34 Buy/Sell $69.65 13.89%
MRK Stock Forecast MERCK Kommanditgesellschaft au... Outperform 18
158.55€ Buy/Sell 147.51€ 32.45%

AstraZeneca PLC Net Income Forecast for 2022 - 2025 - 2030

In the last three years, AstraZeneca PLC's Net Income has gone down from £2.16B to £112.00M – a 94.80% drop. For next year, the 0 analysts predict Net Income of £1.18B, which would mean an increase of 957.74%. Over the next nine years, the pros' prediction is Net Incomeof £1.89T, which would mean a nine-year growth forecast of 1690723.96%.

2022 NI Forecast
£1.18B
2023 NI Forecast
£12.65B
2024 NI Forecast
£136.35B
2025 NI Forecast
£259.94B
2026 NI Forecast
£458.27B
2027 NI Forecast
£735.60B
2028 NI Forecast
£1050.73B
2029 NI Forecast
£1439.40B
2030 NI Forecast
£1893.72B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BDX Stock Forecast Becton, Dickinson and Outperform 17
$231.64 Buy/Sell $278.08 20.88%
GSK Stock Forecast GSK Outperform 16
£13.25 Buy/Sell £16.08 43.02%
4568 Stock Forecast Daiichi Sankyo Company Outperform 18
¥4.00k Buy/Sell ¥0.00 17.65%

AstraZeneca PLC EBITDA Forecast for 2022 - 2025 - 2030

In the last three years, AstraZeneca PLC's EBITDA has grown, increasing from £4.49B to £8.37B – a growth of 86.32%. The next year looks promising for AstraZeneca PLC, with analysts predicting EBITDA of £9.94B – an increase of 18.72%. Over the next nine years, experts anticipate that AstraZeneca PLC's EBITDA will grow at a rate of 233.63%.

2022 EBITDA Forecast
£9.94B
2023 EBITDA Forecast
£11.65B
2024 EBITDA Forecast
£13.57B
2025 EBITDA Forecast
£15.59B
2026 EBITDA Forecast
£17.77B
2027 EBITDA Forecast
£20.10B
2028 EBITDA Forecast
£22.56B
2029 EBITDA Forecast
£25.17B
2030 EBITDA Forecast
£27.93B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
MRNA Stock Forecast Moderna Outperform 11
$119.69 Buy/Sell $0.00 60.83%
BAYN Stock Forecast Bayer Outperform 7
48.37€ Buy/Sell 67.79€ 64.36%
4519 Stock Forecast Chugai Pharmaceutical Hold 18
¥3.42k Buy/Sell ¥0.00 31.66%

AstraZeneca PLC EBIT Forecast for 2022 - 2025 - 2030

In the last three years, AstraZeneca PLC's EBIT has grown by 159.16%, from £1.76B to £4.57B. For the next year, analysts are expecting EBIT to reach £5.75B – an increase of 25.82%. Over the next nine years, experts predict that EBIT will grow by 259.37%.

2022 EBIT Forecast
£5.75B
2023 EBIT Forecast
£6.79B
2024 EBIT Forecast
£7.81B
2025 EBIT Forecast
£9.08B
2026 EBIT Forecast
£10.37B
2027 EBIT Forecast
£11.73B
2028 EBIT Forecast
£13.22B
2029 EBIT Forecast
£14.77B
2030 EBIT Forecast
£16.42B
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
BAS Stock Forecast BASF Outperform 11
39.81€ Buy/Sell 78.27€ 38.16%
LONN Stock Forecast Lonza Group Ltd Outperform 16
CHF440.20 Buy/Sell CHF756.46 78.90%
BNTX Stock Forecast BioNTech Outperform 12
$127.65 Buy/Sell $0.00 56.99%

AstraZeneca PLC EPS Price Prediction Forecast for 2022 - 2025 - 2030

AstraZeneca PLC's EPS has grown in the last three years, jumping from £3.46 to £5.29 – an increase of 52.89%. In the next year, analysts predict that EPS will reach £5.96 – an increase of 12.70%. For the next nine years, the forecast is for EPS to grow by 198.83%.

2022 EPS Forecast
£5.96
2023 EPS Forecast
£6.92
2024 EPS Forecast
£8.05
2025 EPS Forecast
£9.11
2026 EPS Forecast
£10.30
2027 EPS Forecast
£11.58
2028 EPS Forecast
£12.90
2029 EPS Forecast
£14.32
2030 EPS Forecast
£15.81
Ticker Name Consensus Stock Rating Price Buy/Sell Price Target Upside/Downside
ILMN Stock Forecast Illumina Outperform 16
$184.12 Buy/Sell $251.56 30.62%
BIIB Stock Forecast Biogen Outperform 11
$195.75 Buy/Sell $242.78 16.22%
BAX Stock Forecast Baxter International Outperform 17
$54.91 Buy/Sell $69.92 25.66%